Texas Drug Penalty Groups

consists of: (1) the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: • Alfentanil;
• Allylprodine;
• Alphacetylmethadol;
• Benzethidine;
• Betaprodine;
• Clonitazene;
• Diampromide;
• Diethylthiambutene;
• Difenoxin not listed in Penalty Group 3 or 4;
• Dimenoxadol;
• Dimethylthiambutene;
• Dioxaphetyl butyrate;
• Dipipanone;
• Ethylmethylthiambutene;
• Etonitazene;
• Etoxeridine;
• Furethidine;
• Hydroxypethidine;
• Ketobemidone;
• Levophenacylmorphan;
• Meprodine;
• Methadol;
• Moramide;
• Morpheridine;
• Noracymethadol;
• Norlevorphanol;
• Normethadone;
• Norpipanone;
• Phenadoxone;
• Phenampromide;
• Phenomorphan;
• Phenoperidine;
• Piritramide;
• Proheptazine;
• Properidine;
• Propiram;
• Sufentanil;
• Tilidine; and
• Trimeperidine;
(2) the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, if the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
• Acetorphine;
• Acetyldihydrocodeine;
• Benzylmorphine;
• Codeine methylbromide;
• Codeine-N-Oxide;
• Cyprenorphine;
• Desomorphine;
• Dihydromorphine;
• Drotebanol;
• Etorphine, except hydrochloride salt;
• Heroin;
• Hydromorphinol;
• Methyldesorphine;
• Methyldihydromorphine;
• Monoacetylmorphine;
• Morphine methylbromide;
• Morphine methylsulfonate;
• Morphine-N-Oxide;
• Myrophine;
• Nicocodeine;
• Nicomorphine;
• Normorphine;
• Pholcodine; and
• Thebacon;
(3) the following substances, however produced, except those narcotic drugs listed in another group: (A) Opium and opiate not listed in Penalty Group 3 or 4, and a salt, compound, derivative, or preparation of opium or opiate, other than thebaine derived butorphanol, nalmefene and its salts, naloxone and its salts, and naltrexone and its salts, but including:
• Codeine not listed in Penalty Group 3 or 4
• Dihydroetorphine
• Ethylmorphine not listed in Penalty Group 3 or 4
• Granulated opium
• Hydrocodone not listed in Penalty Group 3
• Hydromorphone
• Metopon
• Morphine not listed in Penalty Group 3
• Opium extracts
• Opium fluid extracts
• Oxycodone
• Oxymorphone
• Powdered opium
• Raw opium
• Thebaine; and
• Tincture of opium;
(B) a salt, compound, isomer, derivative, or preparation of a substance that is chemically equivalent or identical to a substance described by Paragraph (A), other than the isoquinoline alkaloids of opium;
(C) Opium poppy and poppy straw;
(D) Cocaine, including:
• its salts, its optical, position, and geometric isomers, and the salts of those isomers;
• coca leaves and a salt, compound, derivative, or preparation of coca leaves;
• a salt, compound, derivative, or preparation of a salt, compound, or derivative that is chemically equivalent or identical to a substance described by Subparagraph (i) or (ii), other than decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine; and
(E) concentrate of poppy straw, meaning the crude extract of poppy straw in liquid, solid, or powder form that contains the phenanthrine alkaloids of the opium poppy;
(4) the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, if the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:
• Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl) -4-piperidinyl]-N-phenylacetamide);
• Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropana mide);
• Alphaprodine;
• Anileridine;
• Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl] -N-phenylpropanamide);
• Beta-hydroxy-3-methylfentanyl;
• Bezitramide;
• Carfentanil;
• Dihydrocodeine not listed in Penalty Group 3 or 4;
• Diphenoxylate not listed in Penalty Group 3 or 4;
• Fentanyl or alpha-methylfentanyl, or any other derivative of Fentanyl;
• Isomethadone;
• Levomethorphan;
• Levorphanol;
• Metazocine;
• Methadone;
• Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
• 3-methylfentanyl(N-[3-methyl-1-(2-phenylethyl)- 4-piperidyl]-N- phenylpropanamide);
• 3-methylthiofentanyl(N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-N – phenylpropanamide);
• Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane- carboxylic acid;
• Para-fluorofentanyl(N-(4-fluorophenyl)-N-1- (2-phenylethyl)-4- piperidinylpropanamide);
• PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
• Pethidine (Meperidine);
• Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
• Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4 carboxylate;
• Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
• Phenazocine;
• Piminodine;
• Racemethorphan;
• Racemorphan;
• Remifentanil; and
• Thiofentanyl(N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]- propanamide);
(5) Flunitrazepam ( trade or other name: Rohypnol);
(6) Methamphetamine, including its salts, optical isomers, and salts of optical isomers;
(7) Phenylacetone and methylamine, if possessed together with intent to manufacture methamphetamine;
(8) Phencyclidine, including its salts;
(9) Gamma hydroxybutyric acid (some trade or other names: gamma hydroxybutyrate, GHB), including its salts; and
(10) Ketamine.

Penalty Group 1-A consists of consists of:

(1) lysergic acid diethylamide (LSD), including its salts, isomers, and salts of isomers; and
(2) compounds structurally derived from 2,5-dimethoxyphenethylamine by substitution at the 1-amino nitrogen atom with a benzyl substituent, including:
(A) compounds further modified by:
(i) substitution in the phenethylamine ring at the 4-position to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents); or
(ii) substitution in the benzyl ring to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents); and
(B) by example, compounds such as:
• 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25B-NBOMe, 2C-B-NBOMe);
• 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25C-NBOMe, 2C-C-NBOMe);
• 2,5-Dimethoxy-4-methyl-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25D-NBOMe, 2C-D-NBOMe);
• 4-Ethyl-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25E-NBOMe, 2C-E-NBOMe);
• 2,5-Dimethoxy-N-(2- methoxybenzyl)phenethylamine (some trade and other names: 25H-NBOMe, 2C-H-NBOMe);
• 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (some trade and other names: 25I-NBOMe, 2C-I-NBOMe);
• 4-Iodo-2,5-dimethoxy-N- benzylphenethylamine (trade or other name: 25I-NB);
• 4-Iodo-2,5-dimethoxy-N-(2,3- methylenedioxybenzyl)phenethylamine (trade or other name: 25I-NBMD);
• 4-Iodo-2,5-dimethoxy-N-(2- fluorobenzyl)phenethylamine (trade or other name: 25I-NBF);
• 4-Iodo-2,5-dimethoxy-N-(2-hydroxybenzyl)phenethylamine (trade or other name: 25I-NBOH);
• 2,5-Dimethoxy-4-nitro-N-(2-methoxybenzyl)phenethylamine (trade or other names: 25N-NBOMe, 2C-N-NBOMe); and
• 2,5-Dimethoxy-4-(n)-propyl-N-(2- methoxybenzyl)phenethylamine (some trade and other names: 25P-NBOMe, 2C-P-NBOMe).
(b) To the extent Subsection (a)(2) conflicts with another provision of this subtitle or another law, the other provision or the other law prevails.

Penalty Group 2 consists of:

(1) any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, if the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
• 5-(2-aminopropyl)benzofuran (5-APB);
• 6-(2-aminopropyl)benzofuran (6-APB);
• 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
• 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
• 5-(2-aminopropyl)indole (5-IT,5-API);
• 6-(2-aminopropyl)indole (6-IT,6-API);
• 1-(benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB);
• 1-(benzofuran-6-yl)-N-methylpropan-2-amine (6-MAPB);
• Benzothiophenylcyclohexylpiperidine (BTCP);
• 8-bromo-alpha-methyl-benzo[1,2-b:4,5-b’]difuran- 4-ethanamine (trade or other name: Bromo-DragonFLY);
• Desoxypipradrol (2-benzhydrylpiperidine);
• 2, 5-dimethoxyamphetamine (some trade or other names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA);
• Diphenylprolinol (diphenyl(pyrrolidin-2-yl) methanol, D2PM);
• Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product (some trade or other names for Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- (trans)- tetrahydrocannabinol);
• Ethylamine Analog of Phencyclidine (some trade or other names: N-ethyl-1-phenylcyclohexylamine, (1- phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE);
• 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone (trade or other name: methoxetamine);
• Ibogaine (some trade or other names: 7-Ethyl-6, 6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- pyrido [1′, 2′:1, 2] azepino [5, 4-b] indole; tabernanthe iboga.);
• 5-iodo-2-aminoindane (5-IAI);
• Mescaline;
• 5-methoxy-3, 4-methylenedioxy amphetamine;
• 4-methoxyamphetamine (some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; PMA);
• 4-methoxymethamphetamine (PMMA);
• 2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone (some trade and other names: 2-MeO-ketamine; methoxyketamine);
• 1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, PPMP);
• 4-methyl-2, 5-dimethoxyamphetamine (some trade and other names: 4-methyl-2, 5-dimethoxy-alpha- methylphenethylamine; “DOM”; “STP”);
• 3,4-methylenedioxy methamphetamine (MDMA, MDM);
• 3,4-methylenedioxy amphetamine;
• 3,4-methylenedioxy N-ethylamphetamine (Also known as N-ethyl MDA);
• 5,6-methylenedioxy-2-aminoindane (MDAI);
• Nabilone (Another name for nabilone: (+)-trans- 3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, 6-dimethyl-9H-dibenzo[b,d] pyran-9-one;
• N-benzylpiperazine (some trade or other names: BZP; 1-benzylpiperazine);
• N-ethyl-3-piperidyl benzilate;
• N-hydroxy-3,4-methylenedioxyamphetamine (Also known as N-hydroxy MDA);
• 4-methylaminorex;
• N-methyl-3-piperidyl benzilate;
• Parahexyl (some trade or other names: 3-Hexyl-1- hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] pyran; Synhexyl);
• 1-Phenylcyclohexylamine;
• 1-Piperidinocyclohexanecarbonitrile (PCC);
• Pyrrolidine Analog of Phencyclidine (some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP);
• Tetrahydrocannabinols, other than marihuana, and synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as:
• delta-1 cis or trans tetrahydrocannabinol, and their optical isomers;
• delta-6 cis or trans tetrahydrocannabinol, and their optical isomers;
• delta-3, 4 cis or trans tetrahydrocannabinol, and its optical isomers; or
• compounds of these structures, regardless of numerical designation of atomic positions, since nomenclature of these substances is not internationally standardized;
• Thiophene Analog of Phencyclidine (some trade or other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl Analog of Phencyclidine; TPCP, TCP);
• 1-pyrrolidine (some trade or other name: TCPy);
• 1-(3-trifluoromethylphenyl)piperazine (trade or other name: TFMPP); and
• 3,4,5-trimethoxy amphetamine;
(2) Phenylacetone (some trade or other names: Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl ketone);
(3) unless specifically excepted or unless listed in another Penalty Group, a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant or stimulant effect on the central nervous system:
• Aminorex (some trade or other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5- phenyl-2-oxazolamine);
• Amphetamine, its salts, optical isomers, and salts of optical isomers;
• Cathinone (some trade or other names: 2-amino-1- phenyl-1-propanone, alpha-aminopropiophenone, 2- aminopropiophenone);
• Etaqualone and its salts;
• Etorphine Hydrochloride;
• Fenethylline and its salts;
• Lisdexamfetamine, including its salts, isomers, and salts of isomers;
• Mecloqualone and its salts;
• Methaqualone and its salts;
• Methcathinone (some trade or other names: 2- methylamino-propiophenone; alpha-(methylamino)propriophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N- methylaminopropriophenone; monomethylpropion; ephedrone, N- methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR 1431);
• N-Ethylamphetamine, its salts, optical isomers, and salts of optical isomers; and
• N,N-dimethylamphetamine (some trade or other names: N,N,alpha-trimethylbenzeneethanamine; N,N,alpha-trimethylphenethylamine), its salts, optical isomers, and salts of optical isomers;
(4) any compound structurally derived from 2-aminopropanal by substitution at the 1-position with any monocyclic or fused-polycyclic ring system, including:
(A) compounds further modified by:
(i) substitution in the ring system to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents), whether or not further substituted in the ring system by other substituents;
(ii) substitution at the 3-position with an alkyl substituent; or
(iii) substitution at the 2-amino nitrogen atom with alkyl, benzyl, dialkyl, or methoxybenzyl groups, or inclusion of the 2-amino nitrogen atom in a cyclic structure; and
(B) by example, compounds such as:
• 4-Methylmethcathinone (Also known as Mephedrone);
• 3,4-Dimethylmethcathinone (Also known as 3,4-DMMC);
• 3-Fluoromethcathinone (Also known as 3-FMC);
• 4-Fluoromethcathinone (Also known as Flephedrone);
• 3,4-Methylenedioxy-N-methylcathinone (Also known as Methylone);
• 3,4-Methylenedioxypyrovalerone (Also known as MDPV);
• alpha-Pyrrolidinopentiophenone (Also known as alpha-PVP);
• Naphthylpyrovalerone (Also known as Naphyrone);
• alpha-Methylamino-valerophenone (Also known as Pentedrone);
• beta-Keto-N-methylbenzodioxolylpropylamine (Also known as Butylone);
• beta-Keto-N-methylbenzodioxolylpentanamine (Also known as Pentylone);
• beta-Keto-Ethylbenzodioxolylbutanamine (Also known as Eutylone); and
• 3,4-methylenedioxy-N-ethylcathinone (Also known as Ethylone);
(5) any compound structurally derived from tryptamine (3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine:
(A) by modification in any of the following ways:
(i) by substitution at the amine nitrogen atom of the sidechain to any extent with alkyl or alkenyl groups or by inclusion of the amine nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;
(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain (alpha-position) with an alkyl or alkenyl group;
(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioaklyl, alkylenedioxy, or halide substituents; or
(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent; and
(B) including:
(i) ethers and esters of the controlled substances listed in this subdivision; and
(ii) by example, compounds such as:
• alpha-ethyltryptamine;
• alpha-methyltryptamine;
• Bufotenine (some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; 5-hydroxy-N, N- dimethyltryptamine; mappine);
• Diethyltryptamine (some trade and other names: N, N-Diethyltryptamine, DET);
• Dimethyltryptamine (trade or other name: DMT);
• 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DiPT);
• O-Acetylpsilocin (Trade or other name: 4-Aco-DMT);
• Psilocin; and
• Psilocybin;
(6) 2,5-Dimethoxyphenethylamine and any compound structurally derived from 2,5-Dimethoxyphenethylamine by substitution at the 4-position of the phenyl ring to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents), including, by example, compounds such as:
• 4-Bromo-2,5-dimethoxyphenethylamine (trade or other name: 2C-B);
• 4-Chloro-2,5-dimethoxyphenethylamine (trade or other name: 2C-C);
• 2,5-Dimethoxy-4-methylphenethylamine (trade or other name: 2C-D);
• 4-Ethyl-2,5-dimethoxyphenethylamine (trade or other name: 2C-E);
• 4-Iodo-2,5-dimethoxyphenethylamine (trade or other name: 2C-I);
• 2,5-Dimethoxy-4-nitrophenethylamine (trade or other name: 2C-N);
• 2,5-Dimethoxy-4-(n)-propylphenethylamine (trade or other name: 2C-P);
• 4-Ethylthio-2,5-dimethoxyphenethylamine (trade or other name: 2C-T-2);
• 4-Isopropylthio-2,5-dimethoxyphenethylamine (trade or other name: 2C-T-4); and
• 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (trade or other name: 2C-T-7); and
(7) 2,5-Dimethoxyamphetamine and any compound structurally derived from 2,5-Dimethoxyamphetamine by substitution at the 4-position of the phenyl ring to any extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents), including, by example, compounds such as:
• 4-Ethylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-2);
• 4-Isopropylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-4);
• 4-Bromo-2,5-dimethoxyamphetamine (trade or other name: DOB);
• 4-Chloro-2,5-dimethoxyamphetamine (trade or other name: DOC);
• 2,5-Dimethoxy-4-ethylamphetamine (trade or other name: DOET);
• 4-Iodo-2,5-dimethoxyamphetamine (trade or other name: DOI);
• 2,5-Dimethoxy-4-methylamphetamine (trade or other name: DOM);
• 2,5-Dimethoxy-4-nitroamphetamine (trade or other name: DON);
• 4-Isopropyl-2,5-dimethoxyamphetamine (trade or other name: DOIP); and
• 2,5-Dimethoxy-4-(n)-propylamphetamine (trade or other name: DOPR).
(b) For the purposes of Subsection (a)(1) only, the term “isomer” includes an optical, position, or geometric isomer.
(c) To the extent Subsection (a)(4), (5), (6), or (7) conflicts with another provision or this subtitle or another law, the other provision or the other law prevails. If a substance listed in this section is also listed in another penalty group, the listing in the other penalty group controls.

Penalty Group 2-A (PG2A, PG2-A)

(a) In this section:
(1) “Core component” is one of the following: azaindole, benzimidazole, benzothiazole, carbazole, imidazole, indane, indazole, indene, indole, pyrazole, pyrazolopyridine, pyridine, or pyrrole.
(2) “Group A component” is one of the following: adamantane, benzene, cycloalkylmethyl, isoquinoline, methylpiperazine, naphthalene, phenyl, quinoline, tetrahydronaphthalene, tetramethylcyclopropane, amino oxobutane, amino dimethyl oxobutane, amino phenyl oxopropane, methyl methoxy oxobutane, methoxy dimethyl oxobutane, methoxy phenyl oxopropane, or an amino acid.
(3) “Link component” is one of the following functional groups: carboxamide, carboxylate, hydrazide, methanone (ketone), ethanone, methanediyl (methylene bridge), or methine.
(b) Penalty Group 2-A consists of any material, compound, mixture, or preparation that contains any quantity of a natural or synthetic chemical substance, including its salts, isomers, and salts of isomers, listed by name in this subsection or contained within one of the structural classes defined in this subsection:
(1) WIN-55,212-2;
(2) Cyclohexylphenol: any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not substituted in the cyclohexyl ring to any extent, including:
• JWH-337;
• JWH-344;
• CP-55,940;
• CP-47,497; and
• analogues of CP-47,497;
(3) Cannabinol derivatives, except where contained in marihuana, including tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, such as:
• Nabilone;
• HU-210; and
• HU-211;
(4) Tetramethylcyclopropyl thiazole: any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including:
• A-836,339;
(5) any compound containing a core component substituted at the 1-position to any extent, and substituted at the 3-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including:
• Naphthoylindane;
• Naphthoylindazole (THJ-018);
• Naphthyl methyl indene (JWH-171);
• Naphthoylindole (JWH-018);
• Quinolinoyl pyrazole carboxylate (Quinolinyl fluoropentyl fluorophenyl pyrazole carboxylate);
• Naphthoyl pyrazolopyridine; and
• Naphthoylpyrrole (JWH-030);
(6) any compound containing a core component substituted at the 1-position to any extent, and substituted at the 2-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including:
• Naphthoylbenzimidazole (JWH-018 Benzimidazole); and
• Naphthoylimidazole;
(7) any compound containing a core component substituted at the 3-position to any extent, and substituted at the 2-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including:
• Naphthoyl benzothiazole; and
(8) any compound containing a core component substituted at the 9-position to any extent, and substituted at the 3-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including:
• Naphthoylcarbazole (EG-018).

Penalty Group 3 consists of:

(1) a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:
• Methylphenidate and its salts; and
• Phenmetrazine and its salts;
(2) a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
• a substance that contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid not otherwise described by this subsection;
• a compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of these, and one or more active medicinal ingredients that are not listed in any penalty group;
• a suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs, and approved by the United States Food and Drug Administration for marketing only as a suppository;
• Alprazolam;
• Amobarbital;
• Bromazepam;
• Camazepam;
• Carisoprodol;
• Chlordiazepoxide;
• Chlorhexadol;
• Clobazam;
• Clonazepam;
• Clorazepate;
• Clotiazepam;
• Cloxazolam;
• Delorazepam;
• Diazepam;
• Estazolam;
• Ethyl loflazepate;
• Etizolam;
• Fludiazepam;
• Flurazepam;
• Glutethimide;
• Halazepam;
• Haloxzolam;
• Ketazolam;
• Loprazolam;
• Lorazepam;
• Lormetazepam;
• Lysergic acid, including its salts, isomers, and salts of isomers;
• Lysergic acid amide, including its salts, isomers, and salts of isomers;
• Mebutamate;
• Medazepam;
• Methyprylon;
• Midazolam;
• Nimetazepam;
• Nitrazepam;
• Nordiazepam;
• Oxazepam;
• Oxazolam;
• Pentazocine, its salts, derivatives, or compounds or mixtures thereof;
• Pentobarbital;
• Pinazepam;
• Prazepam;
• Quazepam;
• Secobarbital;
• Sulfondiethylmethane;
• Sulfonethylmethane;
• Sulfonmethane;
• Temazepam;
• Tetrazepam;
• Tiletamine and zolazepam in combination, and its salts. (some trade or other names for a tiletamine-zolazepam combination product: Telazol, for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, and for zolazepam: 4-(2-fluorophenyl)-6, 8-dihydro-1,3,8,-trimethylpyrazolo-[3,4-e](1,4)-d diazepin-7(1H)-one, flupyrazapon);
• Tramadol;
• Triazolam;
• Zaleplon;
• Zolpidem; and
• Zopiclone
(3) Nalorphine;
• (4) a material, compound, mixture, or preparation containing limited quantities of the following narcotic drugs, or any of their salts:
• not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
• not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
• not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
• not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
• not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
• not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
• not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
• not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; and
• not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;
(5) a material, compound, mixture, or preparation that contains any quantity of the following substances:
• Barbital;
• Chloral betaine;
• Chloral hydrate;
• Ethchlorvynol;
• Ethinamate;
• Meprobamate;
• Methohexital;
• Methylphenobarbital (Mephobarbital);
• Paraldehyde;
• Petrichloral; and
• Phenobarbital;

(6) Peyote, unless unharvested and growing in its natural state, meaning all parts of the plant classified botanically as Lophophora, whether growing or not, the seeds of the plant, an extract from a part of the plant, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds, or extracts;

(7) unless listed in another penalty group, a material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including the substance’s salts, optical, position, or geometric isomers, and salts of the substance’s isomers, if the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
• Benzphetamine;
• Cathine [(+)-norpseudoephedrine];
• Chlorphentermine;
• Clortermine;
• Diethylpropion;
• Fencamfamin;
• Fenfluramine;
• Fenproporex;
• Mazindol;
• Mefenorex;
• Modafinil;
• Pemoline (including organometallic complexes and their chelates);
• Phendimetrazine;
• Phentermine;
• Pipradrol;
• Sibutramine; and
• SPA [(-)-1-dimethylamino-1,2-diphenylethane];

(8) unless specifically excepted or unless listed in another penalty group, a material, compound, mixture, or preparation that contains any quantity of the following substance, including its salts: Dextropropoxyphene (Alpha-(+)- 4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);

(9) an anabolic steroid, including any drug or hormonal substance, or any substance that is chemically or pharmacologically related to testosterone, other than an estrogen, progestin, dehydroepiandrosterone, or corticosteroid, and promotes muscle growth, including the following drugs and substances and any salt, ester, or ether of the following drugs and substances:
• Androstanediol;
• Androstanedione;
• Androstenediol;
• Androstenedione;
• Bolasterone;
• Boldenone;
• Calusterone;
• Clostebol;
• Dehydrochlormethyltestosterone;
• Delta-1-dihydrotestosterone;
• Dihydrotestosterone (4-dihydrotestosterone);
• Drostanolone;
• Ethylestrenol;
• Fluoxymesterone;
• Formebulone;
• Furazabol;
• 13beta-ethyl-17beta-hydroxygon-4-en-3-one;
• 4-hydroxytestosterone;
• 4-hydroxy-19-nortestosterone;
• Mestanolone;
• Mesterolone;
• Methandienone;
• Methandriol;
• Methenolone;
• 17alpha-methyl-3beta, 17 beta-dihydroxy-5alpha- androstane;
• 17alpha-methyl-3alpha, 17 beta-dihydroxy-5alpha- androstane;
• 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4- ene;
• 17alpha-methyl-4-hydroxynandrolone;
• Methyldienolone;
• Methyltestosterone;
• Methyltrienolone;
• 17alpha-methyl-delta-1-dihydrotestosterone;
• Mibolerone;
• Nandrolone;
• Norandrostenediol;
• Norandrostenedione;
• Norbolethone;
• Norclostebol;
• Norethandrolone;
• Normethandrolone;
• Oxandrolone;
• Oxymesterone;
• Oxymetholone;
• Stanozolol;
• Stenbolone;
• Testolactone;
• Testosterone;
• Tetrahydrogestrinone; and
• Trenbolone; and
(10) Salvia divinorum, unless unharvested and growing in its natur al state, meaning all parts of that plant, whether growing or not, the seeds of that plant, an extract from a part of that plant, and every compound, manufacture, salt, derivative, mixture, or preparation of that plant, its seeds, or extracts, including Salvinorin A.
(b) Penalty Group 3 does not include a compound, mixture, or preparation containing a stimulant substance listed in Subsection (a)

(1) if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant effect on the central nervous system and if the admixtures are included in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances that have a stimulant effect on the central nervous system.

(c) Penalty Group 3 does not include a compound, mixture, or preparation containing a depressant substance listed in Subsection (a)(2) or (a)(5) if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system and if the admixtures are included in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances that have a depressant effect on the central nervous system.

Penalty Group 4 consists of:

(1) a compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs that includes one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer on the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
• not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
• not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
• not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
• not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
• not more than 15 milligrams of opium per 29.5729 milliliters or per 28.35 grams; and
• not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;
(2) unless specifically excepted or unless listed in another penalty group, a material, compound, mixture, or preparation containing any quantity of the narcotic drug Buprenorphine or Butorphanol or a salt of either; and
(3) unless specifically exempted or excluded or unless listed in another penalty group, any material, compound, mixture, or preparation that contains any quantity of pyrovalerone, a substance having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.

Possession of less than 2 ounces: Class B Misdemeanor
Possession of 2 to 4 ounces: Class A Misdemeanor
Possession of 4 ounces to 5 pounds: State Jail Felony
Possession of 5 to 50 pounds: 3rd Degree Felony
Possession of 50 pounds, up to a ton: 2nd Degree Felony
Possession of more than 1 ton: 1st Degree Felony

(These are punishment ranges for simple possession; penalties are higher for delivery of marijuana.)